MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Glesatinib hydrochloride

CAS No. : 1123838-51-6

MCE 站：Glesatinib hydrochloride

产品活性：Glesatinib hydrochloride (MGCD265 hydrochloride) 是一种具有口服活性的，有效的 MET/SMO 双抑制剂。 Glesatinib hydrochloride 是一种酪氨酸激酶抑制剂，可拮抗非小细胞肺癌 (NSCLC) 中 P 糖蛋白介导的多药耐药性 (MDR)。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：TAM Receptor  |  c-Met/HGFR

In Vitro: Glesatinib hydrochloride (MGCD265 hydrochloride; 0.01-5 μM; for 72 hours) results in a dose-dependent inhibition of cancer cell growth and shows the low IC₅₀ value of 0.08 μM on NSCLC H1299 cells.
Glesatinib hydrochloride (0.01, 0.1, 0.5, 1 μM) significantly increases by several-fold the percentage of apoptotic cells in NSCLC H1299 cells.
Glesatinib hydrochloride has the cytotoxicity to P-gp overexpressing cancer cells KB-C2, SW620/Ad300, HEK293/ABCB1, and their parent cells KB-3-1, SW620, HEK293 cells with the IC₅₀s fell between 5 and 10 μM.
Glesatinib hydrochloride (1, 3 μM; 120 mins) increases the intracellular [³H]-Paclitaxel accumulation and inhibits [³H]-Paclitaxel efflux in cancer cell lines overexpressing P-gp.
Glesatinib hydrochloride (0-40 μM) stimulates the ATPase activity of P-gp transporters in a dose-dependent manner.

In Vivo: Glesatinib hydrochloride (MGCD265 hydrochloride; 15 mg/kg/day; orally; 40 weeks) causes a significant decrease in tumor size.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Lung Cancer Compound Library  |  2-D08  |  PHA-665752  |  2-Phospho-L-ascorbic acid trisodium  |  SGI-7079  |  SU11274  |  SRI 31215 TFA  |  c-Met inhibitor 1  |  X-376  |  TAM-IN-2  |  Tyrosine kinase inhibitor  |  c-met-IN-1  |  Meleagrin  |  Norleual  |  RU-302  |  Ensartinib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。